JANO.es. Biosimilar drugs are new biological versions of existing ones containing the same active principle as these, which have been shown in clinical trials that the EMA requires efficacy and safety similar to the reference biological product. "The implementation of these biosimilars, in the long term, can translate into obvious savings in the health bill, thus favoring the sustainability of the health system", according to Dr. Emilio Martín Mola, one of the coordinators of the II. Course of Biological Therapies of the Spanish Society of Rheumatology (SER), which has been held this weekend in Madrid.

READ MORE